Eiger BioPharmaceuticals (EIGR) is Initiated by Wedbush to Outperform, Price Target at $36

Eiger BioPharmaceuticals (EIGR) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $36. Wedbush advised their investors in a research report released on Jun 2, 2016.

Many Wall Street Analysts have commented on Eiger BioPharmaceuticals. Jefferies Initiated Eiger BioPharmaceuticals on Apr 7, 2016 to “Buy”, Price Target of the shares are set at $35.Eiger BioPharmaceuticals was Initiated by Piper Jaffray to “Overweight” on Mar 24, 2016.

Eiger BioPharmaceuticals

Leave a Reply

Eiger BioPharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eiger BioPharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.